1 tolvaptan, (jynarque) 15MG x 7/45MG x 7 tablet, dosepack 14
Ended Awarded
- Contract number
- 36C26021F0579
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $10,304
Award facts
- Contract value 100% obligated
- $10,303.55 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
About this award
Otsuka America Pharmaceutical Inc. received a delivery order award from the Department of Veterans Affairs' Veterans Integrated Service Network 20 on August 5, 2021, for the supply of Jynarque (tolvaptan) in tablet form—specifically 15mg and 45mg dosages in a 14-day dose pack. The contract, valued at $10,303.55, operates under a firm fixed price arrangement with no set-aside designation and is set for completion by November 2, 2021. The place of performance is Potomac, Maryland. This delivery order falls under Otsuka America Pharmaceutical Inc.'s larger Indefinite Delivery Vehicle with the VA, specifically an $83.3 million Blanket Purchase Agreement for Jynarque issued through the National Acquisition Center under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB).
Jynarque is a specialized pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. Otsuka America Pharmaceutical Inc., a for-profit pharmaceutical manufacturer headquartered in Rockville, Maryland, has established itself as a significant federal contractor to the VA's Veterans Health Administration, supplying critical specialty medications across multiple VA Integrated Service Networks nationwide. The company's $396 million Federal Supply Schedule contract for pharmaceuticals and hematology-related products further demonstrates its substantial capacity to serve federal healthcare systems and support the VA's mission of providing advanced pharmaceutical treatments to veterans.
Quick answers
Who was awarded contract 36C26021F0579?
36C26021F0579 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 20 (Veterans Health Administration) on August 5, 2021.
How much is contract 36C26021F0579 worth?
The government has obligated $10,304 on 36C26021F0579.
Is contract 36C26021F0579 an order under another contract?
Yes. 36C26021F0579 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26021F0579 competed?
The extent of competition for 36C26021F0579 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award